BioTek Instruments Expands into Switzerland
News Jan 27, 2010
BioTek Switzerland was created from a previous partnership with Witec AG in Littau, Switzerland and will be managed by Margrit Limacher, Witec’s founder. Ms. Limacher will also continue management of the existing Witec AG with their focus on life science products at the same location.
“This new company is a logical result of Witec’s successful BioTek division business operations, and is expected to offer the same level of professional service and support for future growth,” noted Margrit Limacher. “Our customers will continue to have unrestricted and competent service and support when evaluating BioTek’s microplate instrumentation solutions.”
Briar Alpert, BioTek President and CEO added, “This enhanced business relationship will allow BioTek Switzerland to be well-connected to BioTek USA’s information systems with complete access to the company’s global scientific and application resources. Ultimately, this means enhanced customer satisfaction for our Swiss customers.”
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
Brian Berridge Set to Manage National Toxicology ProgramNews
The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.READ MORE
Researchers Identify Druggable Genomic Targets in Malaria ParasiteNews
Using whole-genome analysis and chemogenomics, scientists have discovered novel antimalarial drug targets and drug-resistance genes. The researchers analyzed >250 Plasmodium falciparum cell lines, which were resistant to 37 different anti-malarial compounds.READ MORE
Vanderbilt and Lundbeck to Develop a Novel Approach for Treating SchizophreniaNews
Vanderbilt University has signed separate licensing and research collaboration agreements with Lundbeck, to develop a novel approach for treating schizophrenia. The Vanderbilt compounds have been shown in animal models to have antipsychotic-like effects and to improve cognitive performance with low risk of side effects.READ MORE